AEON Biopharma Inc
AEON.WS
AEON.WS was delisted on the 26th of April, 2024.
40 hedge funds and large institutions have $623K invested in AEON Biopharma Inc in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 40 → 40 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
27% less capital invested
Capital invested by funds: $851K → $623K (-$229K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$9.16K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$4.08K |
| 3 |
Walleye Capital
New York
|
+$1.16K |
| 4 |
Walleye Trading
New York
|
+$765 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$66 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$9.53K |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$2.53K |
| 3 |
FTUS
Flow Traders U.S.
New York
|
-$286 |
| 4 |
RCM
Robinson Capital Management
Grosse Pointe Farms,
Michigan
|
-$8 |
| 5 |
CAC
Cowen and Company
New York
|
-$7 |
AEON.WS Hedge Fund Activity: Q4 2023 in Review
40 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma Inc (AEON.WS) for Q4 2023, worth a combined $623K — down 27% from $851K a quarter earlier.
Fund positioning in AEON.WS was balanced in Q4 2023: 1 fund opened new positions, 1 closed out, 4 added to existing stakes and 5 trimmed.
The largest buyer was Shaolin Capital Management, adding an estimated $9.16K. The largest seller was Radcliffe Capital Management, cutting an estimated $9.53K.
- 40 institutional investors held AEON Biopharma Inc (AEON.WS) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $623K of AEON Biopharma Inc stock for Q4 2023, down 27% quarter-over-quarter.
- 1 fund opened new AEON Biopharma Inc positions in Q4 2023 and 1 closed out, a net change of 0 holders.
- The largest AEON Biopharma Inc buyer in Q4 2023 was Shaolin Capital Management, an estimated $9.16K added.
- The largest AEON Biopharma Inc seller in Q4 2023 was Radcliffe Capital Management, an estimated $9.53K sold.
Based on aggregated 13F filings for Q4 2023.